Neoplasms

Symptoms and General Pathology

All Conditions

Musculoskeletal Diseases

Blood and Lymph Conditions

Neoplasm Metastasis

Bone Neoplasms

Bone Marrow Diseases

Neoplastic Processes

Bone Diseases

Hematologic Diseases

Bone Density Conservation Agents

All Drugs and Chemicals

Zoledronic Acid

Participants will receive JMT103 and zoledronic acid placebo.

Participants will receive zoledronic acid and JMT103 placebo.

120 mg by subcutaneous injection every 4 weeks

JMT103

4 mg by intravenous drip (100mL:4mg) every 4 weeks

zoledronic acid

Clinical Trials Information Group officer

Zefei Jiang, M.D

This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors. The purpose of this study is to determine if JMT103 is non-inferior to zoledronic acid.

multicenter, randomized, double-blind clinical Trail

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

A Phase III, Multicenter, Randomized, Double-blind Clinical Trail to Assess JMT103 Compared to Azoledronic Acid for the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors

Shanghai JMT-Bio Inc.

Nutritional and Metabolic Diseases

Hypercalcemia

Syndrome

Paraneoplastic Syndromes

Metabolic Diseases

Calcium Metabolism Disorders

Water-Electrolyte Imbalance

Eligible subjects will receive JMT103 at a dose of 2 mg/kg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 2 mg/kg SC on study days 8 and 15.

2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.

XIUGAO YANG

Jin LI, PHD

The purpose of this study is to determine the potential of JMT103 to treat hypercalcemia of malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates.

This is a Phase I/II, Single arm, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With refractory Hypercalcemia of Malignancy.

A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

A Phase I/II, Single Arm, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory Hypercalcemia of Malignancy

Percentage of Participants With corrected serum calcium (CSC) ≤ 11.5 mg/dL Within 10 Days after First Dose of JMT103

Percentage of Participants With corrected serum calcium (CSC) ≤ 11.5 mg/dL（2.9 mmol/L） by each visit.

Percentage of Participants With corrected serum calcium (CSC) ≤ 10.8 mg/dL（2.7 mmol/L） by each visit.

Change in urine N-telopeptide/urine creatinine (uNTx/uCr)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid	NCT06221072	Imaging Examina...	JMT103 zoledronic acid	18 Years -	Shanghai JMT-Bio Inc.
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid	NCT06221072	Imaging Examina...	JMT103 zoledronic acid	18 Years -	Shanghai JMT-Bio Inc.
A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM	NCT04198480	Hypercalcemia o...	JMT103	18 Years -	Shanghai JMT-Bio Inc.
A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM	NCT04198480	Hypercalcemia o...	JMT103	18 Years -	Shanghai JMT-Bio Inc.
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid	NCT06221072	Imaging Examina...	JMT103 zoledronic acid	18 Years -	Shanghai JMT-Bio Inc.

Spots Global Cancer Trial Database for jmt103

Every month we try and update this database with for jmt103 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for jmt103

Every month we try and update this database with for jmt103 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for jmt103 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.